Literature DB >> 3609144

Suppression of methionine sulfoximine seizures by intranigral gamma-vinyl GABA injection.

H R Toussi, R A Schatz, B L Waszczak.   

Abstract

Studies were undertaken to determine whether enhancement of GABAergic transmission within the substantia nigra could inhibit seizures caused by the novel, long latency convulsant, L-methionine, sulfoximine (MSO; 200 mg/kg i.p.). Bilateral injections of gamma-vinyl GABA (10 micrograms/side) into several brain sites resulted in varying degrees of protection against MSO-induced seizures. However, significant protection was afforded only when gamma-vinyl GABA was infused into the nigra. The protective effect was reduced when injections were made at sites 2 mm dorsal to the nigra, and was further diminished when the drug was injected into the striatum. These results further support the hypothesis that elevation of cerebral GABA levels is protective against a range of experimentally induced seizures, particularly when the substantia nigra is the target of such manipulations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609144     DOI: 10.1016/0014-2999(87)90232-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

2.  Correlation between carbohydrate and catecholamine level impairments in methionine sulfoximine epileptogenic rat brain.

Authors:  T K Hevor; E Aissi; P Delorme
Journal:  Neurochem Res       Date:  1990-09       Impact factor: 3.996

3.  GABAergic interneuron development and function is modulated by the Tsc1 gene.

Authors:  Cary Fu; Bryan Cawthon; William Clinkscales; Adrienne Bruce; Peggy Winzenburger; Kevin C Ess
Journal:  Cereb Cortex       Date:  2011-10-20       Impact factor: 5.357

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.